New J&J CEO Joaquin Du­a­to promis­es an ag­gres­sive M&A hunt in quest to grow phar­ma sales

Joaquin Du­a­to stepped away from the side­line and di­rect­ly in­to the spot­light on Tues­day, de­liv­er­ing his first quar­ter­ly re­view for J&J as its new­ly-tapped CEO af­ter an 11-year run in se­nior posts. And he had some mixed fi­nan­cial news to de­liv­er to­day while lay­ing claim to a string of block­buster drugs in the mak­ing and out­lin­ing an ap­petite for small and medi­um-sized M&A deals.

Du­a­to al­so didn’t ex­act­ly shun large buy­outs when asked about the fu­ture of the com­pa­ny’s medtech busi­ness — where they look to be in ei­ther the top or num­ber 2 po­si­tion in every seg­ment they’re in — even though the bar for get­ting those deals done is so much high­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER